olatorepatide vs ribupatide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

olatorepatide

Developed by Regeneron Pharmaceuticals under a licence from Hansoh Pharmaceutical Group

Phase 3 in Obesitypeptide
Reliable signal

NCT06839664 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2028 · NCT07685808 (registry estimate)

Reported efficacy

Percent Change from Baseline in Body Weight (Baseline, week 48); Percentage of Participants Who Achieve weight loss≥ 5% from Baseline (Baseline, week 48): Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo. (met)

Result source: NCT06839664

ribupatide

Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals

Phase 3 in Obesitypeptide
Reliable signal

NCT06396429 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 567 participants. The sponsor reports weight loss of up to 17.7% with ribupatide, 16.3 percentage points more than placebo, with up to 88.0% of treated participants losing at least 5% of body weight, and describes the trial as positive.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2026 · NCT06974851 (registry estimate)

Reported efficacy

Percentage change from baseline in weight after 48 weeks of treatment (Baseline, Week 48); Proportion of subjects with weight loss of≥5% from baseline after 48 weeks of treatment (Week 48): Mean weight loss at Week 48 (treatment policy estimand): up to 17.7% with HRS9531 (16.3 percentage points placebo-adjusted); up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss (met)

Result source: NCT06396429

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointolatorepatideribupatide
Body weight, % change—Not posted · NCT06839664—Not posted · NCT06396429
Weight loss of 5% or more—Not posted · NCT06839664—Not posted · NCT06396429
Weight loss of 10% or more—Not posted · NCT06839664—Not posted · NCT06396429
Waist circumference, change (cm)—Not posted · NCT06839664—Not posted · NCT06396429

Body weight, % change

olatorepatide
—Not posted · NCT06839664
ribupatide
—Not posted · NCT06396429

Weight loss of 5% or more

olatorepatide
—Not posted · NCT06839664
ribupatide
—Not posted · NCT06396429

Weight loss of 10% or more

olatorepatide
—Not posted · NCT06839664
ribupatide
—Not posted · NCT06396429

Waist circumference, change (cm)

olatorepatide
—Not posted · NCT06839664
ribupatide
—Not posted · NCT06396429
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints

Coverage. olatorepatide: 2 of 2 rows · ribupatide: 2 of 2 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricolatorepatideribupatide
Weight
percent change · % of baseline
No placebo or comparator arm
19.3% @ 48wka,b
NCT06839664 · Phase 3 · sponsor-reported, not registry data
17.7% @ 48wka,b
NCT06396429 · Phase 3 · sponsor-reported, not registry data
Weight Loss 5%
responder rate · % of participants
No placebo or comparator arm
97.2% @ 48wka,b,c
NCT06839664 · Phase 3 · sponsor-reported, not registry data
88%a,b,c
NCT06396429 · Phase 3 · sponsor-reported, not registry data

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.

Type 2 Diabetes

Shared mechanism: GLP-1/GIP receptor (dual) · full Type 2 Diabetes pipeline

olatorepatide

Developed by Regeneron Pharmaceuticals under a licence from Hansoh Pharmaceutical Group

Phase 3 in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT07156500 (registry estimate)

No aligned efficacy figure on record for this race.

ribupatide

Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT06649344 · Phase 3 · completed

This phase 3 trial randomly assigned 884 adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor, to once-weekly ribupatide 4 mg, ribupatide 2 mg or semaglutide 1 mg, with open-label treatment. The primary measure was HbA1c change at week 36, tested for non-inferiority against semaglutide. The company reports that both doses were non-inferior (HbA1c -2.78% and -2.34% against -2.29%) and that 4 mg was statistically superior, so the result is met. The margin and confidence intervals were not published, and the figures come from the company's own release.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07060456 (registry estimate)

Reported efficacy

Change in HbA1c (from baseline to 36 weeks treatment): Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo (met)

Result source: NCT06650007

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointolatorepatideribupatide
HbA1c, change—Trial running · NCT07156500—Not posted · NCT06650007
Body weight, change (kg)—Trial running · NCT07156500—Not posted · NCT06650007
HbA1c below 7%—Trial running · NCT07156500—Not posted · NCT06650007
Fasting plasma glucose, change—Trial running · NCT07156500—Not posted · NCT06650007
3-point MACE (% with event)—Trial running · NCT07156500—Not posted · NCT06650007

HbA1c, change

olatorepatide
—Trial running · NCT07156500
ribupatide
—Not posted · NCT06650007

Body weight, change (kg)

olatorepatide
—Trial running · NCT07156500
ribupatide
—Not posted · NCT06650007

HbA1c below 7%

olatorepatide
—Trial running · NCT07156500
ribupatide
—Not posted · NCT06650007

Fasting plasma glucose, change

olatorepatide
—Trial running · NCT07156500
ribupatide
—Not posted · NCT06650007

3-point MACE (% with event)

olatorepatide
—Trial running · NCT07156500
ribupatide
—Not posted · NCT06650007
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

olatorepatide: no structured comparison results are available for Type 2 Diabetes.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

ribupatide
Primary, HbA1c change from baseline to week 36 (non-inferiority vs semaglutide 1 mg, efficacy estimand): ribupatide 4 mg -2.78%, 2 mg -2.34%, semaglutide -2.29%; non-inferiority achieved for both doses (margin and CI not published), and 4 mg statistically superior to semaglutide, met. NCT06649344 · Phase 3 · design grade: moderate · publication or press release
Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo NCT06650007 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: olatorepatide's landscape · ribupatide's landscape